Regional variations in fluoroquinolone non-susceptibility among Escherichia coli bloodstream infections within the Veterans Healthcare Administration
暂无分享,去创建一个
E. Perencevich | M. Carrel | D. Livorsi | M. Goto | K. Richardson | Bruce H. Alexander | R. Nair | Makoto M. Jones | Jennifer S. McDanel | Brice F. Beck
[1] P. Thuras,et al. Isolation and Characterization of Escherichia coli Sequence Type 131 and Other Antimicrobial-Resistant Gram-Negative Bacilli from Clinical Stool Samples from Veterans , 2016, Antimicrobial Agents and Chemotherapy.
[2] S. Gatermann,et al. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data – The Influence of Different Parameters in a Routine Clinical Microbiology Laboratory , 2016, PloS one.
[3] A. Gardner,et al. Ciprofloxacin resistance in community- and hospital-acquired Escherichia coli urinary tract infections: a systematic review and meta-analysis of observational studies , 2015, BMC Infectious Diseases.
[4] J. Fierer,et al. Clinical and microbiological determinants of infection after transrectal prostate biopsy. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] James R. Johnson,et al. Long-Term Care Facilities Are Reservoirs for Antimicrobial-Resistant Sequence Type 131 Escherichia coli , 2015, Open forum infectious diseases.
[6] P. Polgreen,et al. Transrectal Prostate Biopsy-Associated Prophylaxis and Infectious Complications: Report of a Query to the Emerging Infections Network of the Infectious Diseases Society of America , 2015, Open forum infectious diseases.
[7] W. Bilker,et al. Clinical and Molecular Epidemiology of Escherichia coli Sequence Type 131 among Hospitalized Patients Colonized Intestinally with Fluoroquinolone-Resistant E. coli , 2014, Antimicrobial Agents and Chemotherapy.
[8] James R. Johnson,et al. A New Clone Sweeps Clean: the Enigmatic Emergence of Escherichia coli Sequence Type 131 , 2014, Antimicrobial Agents and Chemotherapy.
[9] M. Kuskowski,et al. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] Maliha Aziz,et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. , 2013, The Journal of infectious diseases.
[11] C. Lohse,et al. Escherichia coli Sequence Type 131 Is a Dominant, Antimicrobial-Resistant Clonal Group Associated with Healthcare and Elderly Hosts , 2013, Infection Control & Hospital Epidemiology.
[12] J. Karlowsky,et al. In Vitro Antimicrobial Resistance of Urinary Escherichia coli Isolates among U.S. Outpatients from 2000 to 2010 , 2012, Antimicrobial Agents and Chemotherapy.
[13] M. Achtman,et al. Molecular epidemiology of extraintestinal pathogenic Escherichia coli isolates from a regional cohort of elderly patients highlights the prevalence of ST131 strains with increased antimicrobial resistance in both community and hospital care settings. , 2011, The Journal of antimicrobial chemotherapy.
[14] Richard Colgan,et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] M. Kuskowski,et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] G. Peirano,et al. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. , 2010, International journal of antimicrobial agents.
[17] E. P. Dellinger,et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] Jessina C. McGregor,et al. Impact of Empiric Antimicrobial Therapy on Outcomes in Patients with Escherichia coli and Klebsiella pneumoniae Bacteremia: A Cohort Study , 2008, BMC infectious diseases.
[19] S. Blot,et al. Comment on: Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. , 2007, The Journal of antimicrobial chemotherapy.
[20] B. Lee,et al. Fluoroquinolone-resistant Escherichia coli Carriage in Long-Term Care Facility , 2005, Emerging infectious diseases.
[21] Sung-Han Kim,et al. Bloodstream Infections Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Mortality and Treatment Outcome, with Special Emphasis on Antimicrobial Therapy , 2004, Antimicrobial Agents and Chemotherapy.
[22] Stephen F Eckel,et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] Daniel J Sexton,et al. Health CareAssociated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired Infections , 2002, Annals of Internal Medicine.
[24] V. Valtonen,et al. Prognostic factors associated with improved outcome ofEscherichia coli bacteremia in a Finnish university hospital , 1997, European Journal of Clinical Microbiology and Infectious Diseases.
[25] F. Tubau,et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] D. Paterson,et al. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. , 2011, The Journal of antimicrobial chemotherapy.
[27] L. Martínez-Martínez,et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. , 2007, The Journal of antimicrobial chemotherapy.
[28] S. Walter,et al. Risk factors for resistance to antimicrobial agents among nursing home residents. , 2003, American journal of epidemiology.